|
04 May 2020 |
Richter entered into an asset purchase agreement with Mycenax for the biosimilar tocilizumab
|
|
02 May 2020 |
U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
|
|
01 May 2020 |
CHMP Grants Positive Opinion for DARZALEX®(daratumumab) Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma
|
|
01 May 2020 |
Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes
|
|
01 May 2020 |
Alexion Receives CHMP Positive Opinion for ULTOMIRIS® (ravulizumab) in Atypical Hemolytic Uremic Syndrome (aHUS)
|
|
30 Apr 2020 |
Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19
|
|
29 Apr 2020 |
RemeGen Announces US FDA Clearance of IND Application to Initiate Phase II Clinical Trial in Urothelial Cancer
|
|
29 Apr 2020 |
Epsilogen Limited Announces Interim phase 1 MOv18 IgE data presented at AACR
|
|
29 Apr 2020 |
Novartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum
|
|
29 Apr 2020 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Use at an Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications
|
|
28 Apr 2020 |
First patient dosed in avdoralimab Phase II clinical trial in COVID-19 patients with severe pneumonia
|
|
28 Apr 2020 |
Immutep Reports Positive Phase II TACTI-002 Data
|
|
28 Apr 2020 |
New 6-year Data for Genentech’s Ocrevus (ocrelizumab) Show Earlier Treatment Initiation Nearly Halves Risk of Needing Walking Aid in Relapsing Multiple Sclerosis
|
|
28 Apr 2020 |
MorphoSys and I-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202/TJ202 in r/r Multiple Myeloma in Mainland China
|
|
28 Apr 2020 |
Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID-19 pneumonia
|
|
28 Apr 2020 |
Novel anti-PD-1 drug was approved for melanoma treatment
|
|
27 Apr 2020 |
Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma
|
|
27 Apr 2020 |
Kamada and Kedrion Biopharma Announce Global Collaboration for the Development, Manufacturing and Distribution of a Plasma-Derived Anti-SARS-CoV-2 (COVID-19) Polyclonal Immunoglobulin Product
|
|
27 Apr 2020 |
Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients
|
|
27 Apr 2020 |
First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I
|
|
27 Apr 2020 |
Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival
|
|
27 Apr 2020 |
MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting
|
|
27 Apr 2020 |
Halozyme Announces Janssen Submits New Drug Application In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma
|
|
27 Apr 2020 |
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
|
|
27 Apr 2020 |
Alligator Bioscience presents promising interim Phase I data for its bispecific drug candidate ATOR-1015 at AACR
|
